Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?
Filippo Pesapane(European Institute of Oncology), Enrico Cassano(European Institute of Oncology), Marta Cremonesi(European Institute of Oncology), Anna Rotili(Ripamonti), Silvia Penco(Ripamonti), Barbara Alicja Jereczek‐Fossa(European Institute of Oncology), Olga Nigro(ATS Sardegna (Italy)), Massimo Bellomi(University of Milan), Graziella Pinotti(Medica (Italy)), Matteo B. Suter(Ospedale di Circolo e Fondazione Macchi)
Cited by 66
Related Papers
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
|European Journal of Nuclear Medicine and Molecular Imaging|2014|465